- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Megestrol Acetate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 152
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 119 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2137–2160
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vitreous Hemorrhage, Diabetic Retinopathy
- Interventions
- Vitrase
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 61
- States / cities
- Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Not listed
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 165
- States / cities
- Pomona, California • Atlantis, Florida • Boynton Beach, Florida + 138 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 508
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
- Conditions
- Type 1 Diabetes
- Interventions
- Verapamil
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Follicular Lymphoma
- Interventions
- Tazemetostat, Rituximab
- Drug · Combination Product
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Boulder, Colorado + 17 more
- Conditions
- Psoriasis
- Interventions
- adalimumab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more
- Conditions
- Kidney Transplant Rejection
- Interventions
- Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
- Diagnostic Test · Other
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
- Conditions
- HIV Infections, Lipodystrophy, Hyperinsulinemia
- Interventions
- Metformin hydrochloride, Rosiglitazone maleate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
- Conditions
- Chronic Pancreatitis
- Interventions
- Pancreatic fully-covered self-expanding metal stent (FCSEMS)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
- Interventions
- NTX-001 (PEG-Fusion)
- Combination Product
- Lead sponsor
- Neuraptive Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Francisco, California • Orlando, Florida + 20 more
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
- Interventions
- Extended release niacin, Simvastatin
- Drug
- Lead sponsor
- Axio Research. LLC
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 3,414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
- Conditions
- Hospitalized Children
- Interventions
- Family Bridge Program
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer
- Interventions
- recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 23
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 16 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-DOTA0-Tyr3-Octreotate
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more
- Conditions
- Bipolar Disorder
- Interventions
- Ramelteon SL, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 134 more
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
- Interventions
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 3
- States / cities
- Salt Lake City, Utah • Seattle, Washington
- Conditions
- Contraception
- Interventions
- Acyline, Testosterone Gel, Depo-Medroxyprogesterone
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pain
- Interventions
- Virtual Reality video distraction, Virtual Reality video game
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Central Precocious Puberty
- Interventions
- Triptorelin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Thyroid Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 10 more
- Conditions
- Prostatic Neoplasms
- Interventions
- LMIS 50 mg
- Drug
- Lead sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- Homewood, Alabama • San Diego, California • Meridian, Idaho + 4 more
- Conditions
- Skin Infections, Bacterial
- Interventions
- Retpamulin Ointment, 1%, Linezolid
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 53
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more